Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief: Lynx Therapeutics

  • News

Executive Summary

Lynx Therapeutics: Glaxo Wellcome is terminating 1994 licensing agreement between Hayward, Calif.-based Lynx and the Wellcome Foundation that covers the development and marketing of Lynx' antisense drug candidate for the prevention of restenosis following coronary angioplasty or balloon dilation. Lynx reports Jan. 11 that the termination is effective March 17. Glaxo Wellcome says the phosphorothioate oligonucleotide is "no longer a good fit" with its pipeline. Lynx is studying the compound in a Phase I trial in Argentina, accruing 60 patients...

Table

View full table

Tags:
Latest Headlines

EU CHMP Opinions And MAA Updates

MHRA Needs ‘Rebuilding’ After Post-Brexit Loss Of Capacity & Industry Investment

EU & South Korea Sign Deal On Exchange Of Confidential Information

Recent And Upcoming FDA Advisory Committee Meetings

See All
UsernamePublicRestriction

Register

PS027486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By